Business
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the vesicular monoamine transporter 2 (VMAT2). Building on nearly 20 years of deep scientific expertise and experience in VMAT2 inhibition, Neurocrine designed NBI-1065890 to potentially deliver a differentiated profile, including the possibility of longer-a
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation, selective inhibitor of the vesicular monoamine transporter 2 (VMAT2). Building on nearly 20 years of deep scientific expertise and experience in VMAT2 inhibition, Neurocrine designed NBI-1065890 to potentially deliver a differentiated profile, including the possibility of longer-acting options for the treatment of TD.","length":579,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Neurocrine Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":74,"url":"https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/T_HafQLyqDkZ5Jiojrk_IQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/9adfb0c84e7d306b48de2742f62d85d4","width":400,"height":74}},"href":"https://mma.prnewswire.com/media/678850/Neurocrine_Biosciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""NBI-'890 is an internally discovered molecule with distinct physical and chemical properties that may allow it to benefit a broader range of patients with tardive dyskinesia," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "Advancing this program to a Phase 2 clinical study is key to our strategy to define the future of VMAT2 biology and deliver lasting impact for patients."","length":429,"tagName":"p"},{"type":"text","content":"This Phase 2, randomized, double-blind, placebo-controlled study will enroll approximately 100 adult subjects with TD and will assess the efficacy, safety, and tolerability of NBI-1065890 compared with placebo. The primary efficacy endpoint is change from baseline in the Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score (sum of Items 1–7) at Week 8.","length":367,"tagName":"p"},{"type":"text","content":"Neurocrine successfully developed and received U.S. Food and Drug Administration approval in 2017 for valbenazine, a selective VMAT2 inhibitor, f...